

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 98,365-B1)

In re Application of:

Rodgers and diZerega

Serial No.: **To be assigned**

Filed: **Herewith**

For: **Method for Accelerating Bone,
Cartilage, and Connective Tissue
Growth**

Art Unit: **To be assigned**

Examiner: **To be assigned**

Asst. Commissioner for Patents
BOX Application
Washington, D.C. 20231

**COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**


Sir,

As required by 37 C.F.R. 1.821(f), the content of the sequence listing paper copy and
computer readable copy are the same.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Dated: January 30, 2001

By:



David Harper
Reg. No. 42,636

<220>
<223> Description of Artificial Sequence: AII (1-7)

<400> 4
Asp Arg Val Tyr Ile His Pro
1 5

<210> 5
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII (2-7)

<400> 5
Arg Val Tyr Ile His Pro
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII (3-7)

<400> 6
Val Tyr Ile His Pro
1 5

<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII (5-8)

<400> 7
Ile His Pro Phe
1

<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII (1-6)

<400> 8
Asp Arg Val Tyr Ile His
1 5

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII (1-5)

<400> 9
Asp Arg Val Tyr Ile
1 5

<210> 10
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII (1-4)

<400> 10
Asp Arg Val Tyr
1

<210> 11
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII (1-3)

<400> 11
Asp Arg Val
1

<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII analogue

<220>
<221> MOD_RES
<222> (2)
<223> Nle

<400> 12
Arg Xaa Tyr Ile His Pro Phe
1 5

<210> 13
<211> 7

<223> Xaa at position 2 can be Val, Ala, Leu, Nle, Ile,
Gly, Pro, Aib, Acp, or Tyr

<220>

<221> UNSURE

<222> (4)

<223> Xaa at position 4 can be Ile, Ala, Leu, Nle, Val,
or Gly

<400> 16

Xaa Xaa Tyr Xaa His Pro Phe
1 5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue

<400> 17

Arg Val Tyr Gly His Pro Phe
1 5

<210> 18

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue

<400> 18

Arg Val Tyr Ala His Pro Phe
1 5

<210> 19

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue 1

<400> 19

Asp Arg Val Tyr Val His Pro Phe
1 5

<210> 20

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue 2

007736040 - 04 APR 74

5

```
<220>  
<221> MOD_RES  
<222> (3)  
<223> Nle
```

[illegible]

<400> 33
Asp Arg Xaa Tyr Ile His Pro Phe
1 5

<210> 34
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII analogue 16

<220>
<221> MOD_RES
<222> (5)
<223> Nle

<400> 34
Asp Arg Val Tyr Xaa His Pro Phe
1 5

<210> 35
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AII analogue 17

<220>
<221> MOD_RES
<222> (4)
<223> homo Ser

<400> 35
Asp Arg Val Ser Tyr Ile His Pro Phe
1 5

<210> 36
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence: p-aminophenylalanine 6 AII

<220>
<221> MOD_RES
<222> (6)
<223> p-aminophenylalanine

<400> 36
Asp Arg Val Tyr Ile Xaa Pro Phe
1 5

<210> 37
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:angiotensin I

<400> 37
Asp Arg Val Tyr Ile His Pro Phe His Leu
1 5 10

<210> 38
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (2)
<223> Orn

<220>
<223> Description of Artificial Sequence:GSD37B:
Orn2-AII

<400> 38
Asp Xaa Val Tyr Ile His Pro Phe
1 5

<210> 39
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:GSD28: Ile8-AII

<400> 39
Asp Arg Val Tyr Ile His Pro Ile
1 5

<210> 40
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:1GD:
Ala4-AII(1-7)

<400> 40
Asp Arg Val Ala Ile His Pro
1 5

<210> 41

<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:2GD:
Pro3-AII(1-7)

<400> 41
Asp Arg Pro Tyr Ile His Pro
1 5

<210> 42
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Gly1-AII

<400> 42
Gly Arg Val Tyr Ile His Pro Phe
1 5

<210> 43
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:GSD38B:Citron2-AII

<220>
<221> MOD_RES
<222> (2)
<223> Citron

<400> 43
Asp Xaa Val Tyr Ile His Pro Phe
1 5

<210> 44
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial
Sequence:Pro3Ala4-AII(1-7)

<400> 44
Asp Arg Pro Ala Ile His Pro
1 5

<210> 45

